Evaluation of Effect of Probiotics on Cytokine Levels in Critically Ill Children With Severe Sepsis: A Double-Blind, Placebo-Controlled Trial. Angurana, S. K, Bansal, A., Singhi, S., Aggarwal, R., Jayashree, M., Salaria, M., & Mangat, N. K Critical Care Medicine, 46(10):1656–1664, October, 2018. ![Evaluation of Effect of Probiotics on Cytokine Levels in Critically Ill Children With Severe Sepsis: A Double-Blind, Placebo-Controlled Trial. [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex OBJECTIVES:To evaluate the effect of probiotics on cytokines in children with severe sepsis. DESIGN:Randomized, double-blind, placebo-controlled trial. SETTING:ICU of a tertiary care teaching hospital in North India. PATIENTS:Children 3 months to 12 years old with severe sepsis. INTERVENTIONS:Enrolled children were randomized to probiotic (n = 50) and placebo (n = 50) groups. Probiotic group received VSL#3 (Danisco-Dupont USA, Madison, WI) (Lactobacillus paracasei, L. plantarum, L. acidophilus, L. delbrueckii, Bifidobacterium longum, B. infantis, B. breve, Streptococcus salivarius; maltose and silicon dioxide), and placebo group received maltose and silicon dioxide. Dose was 1 sachet twice daily for 7 days. Blood was collected on days 1 and 7 for estimation of interleukin-6, interleukin-12p70, interleukin-17, tumor necrosis factor-α, interleukin-10, and transforming growth factor -β1. "Primary outcome": Change in cytokine levels in probiotic and placebo groups from day 1 to 7. "Secondary outcomes": Sequential Organ Failure Assessment score, healthcare-associated infections, ICU stay, and mortality. MEASUREMENTS AND MAIN RESULTS:On day 7, probiotic group had significantly lower levels of proinflammatory cytokines (interleukin-6 [80 vs 186 pg/mL, p = 0.001]; interleukin-12p70 [44 vs 79 pg/mL, p = 0.001]; interleukin-17 [217 vs 293 pg/mL, p = 0.01]; and tumor necrosis factor-α [192 vs 348 pg/mL, p = 0.01]) and higher levels of antiinflammatory cytokines (interleukin-10 [320 vs 240 pg/mL, p = 0.02] and transforming growth factor-β1 [311 vs 221 ng/mL, p = 0.01]) than placebo group. From day 1 to 7, probiotic group showed significant decrease in proinflammatory cytokines (interleukin-6 [196-80 pg/mL, p = 0.001]; interleukin-12p70 [71-44 pg/mL, p = 0.01]; interleukin-17 [258-217 pg/mL, p = 0.01]; and tumor necrosis factor-α [347-192 pg/mL, p = 0.001]) and increase in antiinflammatory cytokines (interleukin-10 [198-320 pg/mL, p = 0.001] and transforming growth factor-β1 [216-311 ng/mL, p = 0.001]) as compared to placebo group. Sequential Organ Failure Assessment score on day 7 was significantly less in probiotic group (1 vs 3). There was a nonsignificant trend toward lower incidence of healthcare-associated infections (14% vs 20%) and duration of ICU stay (6.5 vs 9 d) in probiotic group. Mortality was similar in two groups. CONCLUSIONS:Probiotics supplementation for 7 days resulted in significant decrease in proinflammatory and increase in antiinflammatory cytokines in children with severe sepsis.
@article{angurana_evaluation_2018,
title = {Evaluation of {Effect} of {Probiotics} on {Cytokine} {Levels} in {Critically} {Ill} {Children} {With} {Severe} {Sepsis}: {A} {Double}-{Blind}, {Placebo}-{Controlled} {Trial}.},
volume = {46},
url = {http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29957709&retmode=ref&cmd=prlinks},
doi = {10.1097/ccm.0000000000003279},
abstract = {OBJECTIVES:To evaluate the effect of probiotics on cytokines in children with severe sepsis. DESIGN:Randomized, double-blind, placebo-controlled trial. SETTING:ICU of a tertiary care teaching hospital in North India. PATIENTS:Children 3 months to 12 years old with severe sepsis. INTERVENTIONS:Enrolled children were randomized to probiotic (n = 50) and placebo (n = 50) groups. Probiotic group received VSL\#3 (Danisco-Dupont USA, Madison, WI) (Lactobacillus paracasei, L. plantarum, L. acidophilus, L. delbrueckii, Bifidobacterium longum, B. infantis, B. breve, Streptococcus salivarius; maltose and silicon dioxide), and placebo group received maltose and silicon dioxide. Dose was 1 sachet twice daily for 7 days. Blood was collected on days 1 and 7 for estimation of interleukin-6, interleukin-12p70, interleukin-17, tumor necrosis factor-α, interleukin-10, and transforming growth factor -β1. "Primary outcome": Change in cytokine levels in probiotic and placebo groups from day 1 to 7. "Secondary outcomes": Sequential Organ Failure Assessment score, healthcare-associated infections, ICU stay, and mortality. MEASUREMENTS AND MAIN RESULTS:On day 7, probiotic group had significantly lower levels of proinflammatory cytokines (interleukin-6 [80 vs 186 pg/mL, p = 0.001]; interleukin-12p70 [44 vs 79 pg/mL, p = 0.001]; interleukin-17 [217 vs 293 pg/mL, p = 0.01]; and tumor necrosis factor-α [192 vs 348 pg/mL, p = 0.01]) and higher levels of antiinflammatory cytokines (interleukin-10 [320 vs 240 pg/mL, p = 0.02] and transforming growth factor-β1 [311 vs 221 ng/mL, p = 0.01]) than placebo group. From day 1 to 7, probiotic group showed significant decrease in proinflammatory cytokines (interleukin-6 [196-80 pg/mL, p = 0.001]; interleukin-12p70 [71-44 pg/mL, p = 0.01]; interleukin-17 [258-217 pg/mL, p = 0.01]; and tumor necrosis factor-α [347-192 pg/mL, p = 0.001]) and increase in antiinflammatory cytokines (interleukin-10 [198-320 pg/mL, p = 0.001] and transforming growth factor-β1 [216-311 ng/mL, p = 0.001]) as compared to placebo group. Sequential Organ Failure Assessment score on day 7 was significantly less in probiotic group (1 vs 3). There was a nonsignificant trend toward lower incidence of healthcare-associated infections (14\% vs 20\%) and duration of ICU stay (6.5 vs 9 d) in probiotic group. Mortality was similar in two groups. CONCLUSIONS:Probiotics supplementation for 7 days resulted in significant decrease in proinflammatory and increase in antiinflammatory cytokines in children with severe sepsis.},
number = {10},
journal = {Critical Care Medicine},
author = {Angurana, Suresh K and Bansal, Arun and Singhi, Sunit and Aggarwal, Ritu and Jayashree, Muralidharan and Salaria, Manila and Mangat, Navdeep K},
month = oct,
year = {2018},
pages = {1656--1664},
}
Downloads: 0
{"_id":"jktwTMpdQbbtqmgw9","bibbaseid":"angurana-bansal-singhi-aggarwal-jayashree-salaria-mangat-evaluationofeffectofprobioticsoncytokinelevelsincriticallyillchildrenwithseveresepsisadoubleblindplacebocontrolledtrial-2018","downloads":0,"creationDate":"2019-02-27T00:19:07.138Z","title":"Evaluation of Effect of Probiotics on Cytokine Levels in Critically Ill Children With Severe Sepsis: A Double-Blind, Placebo-Controlled Trial.","author_short":["Angurana, S. K","Bansal, A.","Singhi, S.","Aggarwal, R.","Jayashree, M.","Salaria, M.","Mangat, N. K"],"year":2018,"bibtype":"article","biburl":"http://bibbase.org/zotero-group/gxu917/1345589","bibdata":{"bibtype":"article","type":"article","title":"Evaluation of Effect of Probiotics on Cytokine Levels in Critically Ill Children With Severe Sepsis: A Double-Blind, Placebo-Controlled Trial.","volume":"46","url":"http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29957709&retmode=ref&cmd=prlinks","doi":"10.1097/ccm.0000000000003279","abstract":"OBJECTIVES:To evaluate the effect of probiotics on cytokines in children with severe sepsis. DESIGN:Randomized, double-blind, placebo-controlled trial. SETTING:ICU of a tertiary care teaching hospital in North India. PATIENTS:Children 3 months to 12 years old with severe sepsis. INTERVENTIONS:Enrolled children were randomized to probiotic (n = 50) and placebo (n = 50) groups. Probiotic group received VSL#3 (Danisco-Dupont USA, Madison, WI) (Lactobacillus paracasei, L. plantarum, L. acidophilus, L. delbrueckii, Bifidobacterium longum, B. infantis, B. breve, Streptococcus salivarius; maltose and silicon dioxide), and placebo group received maltose and silicon dioxide. Dose was 1 sachet twice daily for 7 days. Blood was collected on days 1 and 7 for estimation of interleukin-6, interleukin-12p70, interleukin-17, tumor necrosis factor-α, interleukin-10, and transforming growth factor -β1. \"Primary outcome\": Change in cytokine levels in probiotic and placebo groups from day 1 to 7. \"Secondary outcomes\": Sequential Organ Failure Assessment score, healthcare-associated infections, ICU stay, and mortality. MEASUREMENTS AND MAIN RESULTS:On day 7, probiotic group had significantly lower levels of proinflammatory cytokines (interleukin-6 [80 vs 186 pg/mL, p = 0.001]; interleukin-12p70 [44 vs 79 pg/mL, p = 0.001]; interleukin-17 [217 vs 293 pg/mL, p = 0.01]; and tumor necrosis factor-α [192 vs 348 pg/mL, p = 0.01]) and higher levels of antiinflammatory cytokines (interleukin-10 [320 vs 240 pg/mL, p = 0.02] and transforming growth factor-β1 [311 vs 221 ng/mL, p = 0.01]) than placebo group. From day 1 to 7, probiotic group showed significant decrease in proinflammatory cytokines (interleukin-6 [196-80 pg/mL, p = 0.001]; interleukin-12p70 [71-44 pg/mL, p = 0.01]; interleukin-17 [258-217 pg/mL, p = 0.01]; and tumor necrosis factor-α [347-192 pg/mL, p = 0.001]) and increase in antiinflammatory cytokines (interleukin-10 [198-320 pg/mL, p = 0.001] and transforming growth factor-β1 [216-311 ng/mL, p = 0.001]) as compared to placebo group. Sequential Organ Failure Assessment score on day 7 was significantly less in probiotic group (1 vs 3). There was a nonsignificant trend toward lower incidence of healthcare-associated infections (14% vs 20%) and duration of ICU stay (6.5 vs 9 d) in probiotic group. Mortality was similar in two groups. CONCLUSIONS:Probiotics supplementation for 7 days resulted in significant decrease in proinflammatory and increase in antiinflammatory cytokines in children with severe sepsis.","number":"10","journal":"Critical Care Medicine","author":[{"propositions":[],"lastnames":["Angurana"],"firstnames":["Suresh","K"],"suffixes":[]},{"propositions":[],"lastnames":["Bansal"],"firstnames":["Arun"],"suffixes":[]},{"propositions":[],"lastnames":["Singhi"],"firstnames":["Sunit"],"suffixes":[]},{"propositions":[],"lastnames":["Aggarwal"],"firstnames":["Ritu"],"suffixes":[]},{"propositions":[],"lastnames":["Jayashree"],"firstnames":["Muralidharan"],"suffixes":[]},{"propositions":[],"lastnames":["Salaria"],"firstnames":["Manila"],"suffixes":[]},{"propositions":[],"lastnames":["Mangat"],"firstnames":["Navdeep","K"],"suffixes":[]}],"month":"October","year":"2018","pages":"1656–1664","bibtex":"@article{angurana_evaluation_2018,\n\ttitle = {Evaluation of {Effect} of {Probiotics} on {Cytokine} {Levels} in {Critically} {Ill} {Children} {With} {Severe} {Sepsis}: {A} {Double}-{Blind}, {Placebo}-{Controlled} {Trial}.},\n\tvolume = {46},\n\turl = {http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29957709&retmode=ref&cmd=prlinks},\n\tdoi = {10.1097/ccm.0000000000003279},\n\tabstract = {OBJECTIVES:To evaluate the effect of probiotics on cytokines in children with severe sepsis. DESIGN:Randomized, double-blind, placebo-controlled trial. SETTING:ICU of a tertiary care teaching hospital in North India. PATIENTS:Children 3 months to 12 years old with severe sepsis. INTERVENTIONS:Enrolled children were randomized to probiotic (n = 50) and placebo (n = 50) groups. Probiotic group received VSL\\#3 (Danisco-Dupont USA, Madison, WI) (Lactobacillus paracasei, L. plantarum, L. acidophilus, L. delbrueckii, Bifidobacterium longum, B. infantis, B. breve, Streptococcus salivarius; maltose and silicon dioxide), and placebo group received maltose and silicon dioxide. Dose was 1 sachet twice daily for 7 days. Blood was collected on days 1 and 7 for estimation of interleukin-6, interleukin-12p70, interleukin-17, tumor necrosis factor-α, interleukin-10, and transforming growth factor -β1. \"Primary outcome\": Change in cytokine levels in probiotic and placebo groups from day 1 to 7. \"Secondary outcomes\": Sequential Organ Failure Assessment score, healthcare-associated infections, ICU stay, and mortality. MEASUREMENTS AND MAIN RESULTS:On day 7, probiotic group had significantly lower levels of proinflammatory cytokines (interleukin-6 [80 vs 186 pg/mL, p = 0.001]; interleukin-12p70 [44 vs 79 pg/mL, p = 0.001]; interleukin-17 [217 vs 293 pg/mL, p = 0.01]; and tumor necrosis factor-α [192 vs 348 pg/mL, p = 0.01]) and higher levels of antiinflammatory cytokines (interleukin-10 [320 vs 240 pg/mL, p = 0.02] and transforming growth factor-β1 [311 vs 221 ng/mL, p = 0.01]) than placebo group. From day 1 to 7, probiotic group showed significant decrease in proinflammatory cytokines (interleukin-6 [196-80 pg/mL, p = 0.001]; interleukin-12p70 [71-44 pg/mL, p = 0.01]; interleukin-17 [258-217 pg/mL, p = 0.01]; and tumor necrosis factor-α [347-192 pg/mL, p = 0.001]) and increase in antiinflammatory cytokines (interleukin-10 [198-320 pg/mL, p = 0.001] and transforming growth factor-β1 [216-311 ng/mL, p = 0.001]) as compared to placebo group. Sequential Organ Failure Assessment score on day 7 was significantly less in probiotic group (1 vs 3). There was a nonsignificant trend toward lower incidence of healthcare-associated infections (14\\% vs 20\\%) and duration of ICU stay (6.5 vs 9 d) in probiotic group. Mortality was similar in two groups. CONCLUSIONS:Probiotics supplementation for 7 days resulted in significant decrease in proinflammatory and increase in antiinflammatory cytokines in children with severe sepsis.},\n\tnumber = {10},\n\tjournal = {Critical Care Medicine},\n\tauthor = {Angurana, Suresh K and Bansal, Arun and Singhi, Sunit and Aggarwal, Ritu and Jayashree, Muralidharan and Salaria, Manila and Mangat, Navdeep K},\n\tmonth = oct,\n\tyear = {2018},\n\tpages = {1656--1664},\n}\n\n\n\n","author_short":["Angurana, S. K","Bansal, A.","Singhi, S.","Aggarwal, R.","Jayashree, M.","Salaria, M.","Mangat, N. K"],"key":"angurana_evaluation_2018","id":"angurana_evaluation_2018","bibbaseid":"angurana-bansal-singhi-aggarwal-jayashree-salaria-mangat-evaluationofeffectofprobioticsoncytokinelevelsincriticallyillchildrenwithseveresepsisadoubleblindplacebocontrolledtrial-2018","role":"author","urls":{"Paper":"http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29957709&retmode=ref&cmd=prlinks"},"metadata":{"authorlinks":{}},"downloads":0,"html":""},"search_terms":["evaluation","effect","probiotics","cytokine","levels","critically","ill","children","severe","sepsis","double","blind","placebo","controlled","trial","angurana","bansal","singhi","aggarwal","jayashree","salaria","mangat"],"keywords":[],"authorIDs":[],"dataSources":["4P4hKw3sZj97Zz2kx"]}